{"name":"Abdul El-Rabbany","slug":"abdul-el-rabbany","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cefazolin Injection","genericName":"Cefazolin Injection","slug":"cefazolin-injection","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Cefazolin 2 GM Injection","genericName":"Cefazolin 2 GM Injection","slug":"cefazolin-2-gm-injection","indication":"Bacterial infections caused by susceptible organisms (respiratory tract, skin and soft tissue, urinary tract, biliary tract, bone and joint infections)","status":"marketed"}]}],"pipeline":[{"name":"Cefazolin Injection","genericName":"Cefazolin Injection","slug":"cefazolin-injection","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cefazolin 2 GM Injection","genericName":"Cefazolin 2 GM Injection","slug":"cefazolin-2-gm-injection","phase":"marketed","mechanism":"Cefazolin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan.","indications":["Bacterial infections caused by susceptible organisms (respiratory tract, skin and soft tissue, urinary tract, biliary tract, bone and joint infections)","Surgical prophylaxis","Endocarditis prophylaxis in susceptible patients"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}